Coherus BioSciences (CHRS)
(Delayed Data from NSDQ)
$1.91 USD
-0.10 (-4.98%)
Updated May 24, 2024 04:00 PM ET
After-Market: $1.91 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CHRS 1.91 -0.10(-4.98%)
Will CHRS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CHRS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CHRS
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
CHRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inovio Pharma (INO) Stock Rallies 134% in a Month: Here's Why
Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody
Vericel Corporation (VCEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Other News for CHRS
Buy Rating Affirmed for Coherus Biosciences on CHS-114’s Promising Clinical Data and Strong Financial Projections
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
Coherus Biosciences presents preliminary Phase I results of CHS-114
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Johnson & Johnson (JNJ), Eli Lilly & Co (LLY) and Coherus Biosciences (CHRS)